Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

trained immunity natural killer cells IBR900

A preparation of trained immunity natural killer (tiNK) cells, with potential cytolytic and antineoplastic activities. Upon administration, tiNK cells IBR900 recognize and lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	tiNK cells IBR900 tiNKs IBR900 trained immunity NK cells IBR900
Code name:	IBR 900 IBR-900 IBR900

trained immunity natural killer cells IBR900

Search NCI's Drug Dictionary